Protara Therapeutics, Inc. remote jobs and company guide

Protara Therapeutics is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Founded on the principle of applying modern scientific, regulatory, and manufacturing advancements to established mechanisms, the company creates accelerated development opportunities that can bring life-changing treatments to patients faster. Protara's lead investigational therapy, TARA-002, is a cell therapy based on the broad immunopotentiator OK-432, which is already approved in Japan and Taiwan for multiple oncologic indications and lymphatic malformations. The company is evaluating TARA-002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) in the United States, having received Rare Pediatric Disease Designation from the FDA.

In addition to TARA-002, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement therapy designed for patients on parenteral support. Approximately 80% of these patients are choline deficient and have some degree of liver damage, representing a significant unmet medical need. IV Choline Chloride has the potential to become the first FDA-approved IV choline formulation for these patients. The Protara team values creativity, diverse perspectives, and tenacity in their pursuit of novel therapies, operating from their modern office in New York City's Flatiron District with a culture grounded in inclusivity, integrity, and collaboration.